|By PR Newswire||
|September 2, 2013 10:31 AM EDT||
NEW YORK, Sept. 2, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Medicines for bowel inflammation - you explore R&D and potential salesWhat's the future for treating inflammatory bowel diseases (IBD)? Visiongain's updated report gives you revenue predictions from 2013, helping you stay ahead. There you find financial results, R&D trends, opportunities, and potential revenues.
In that work you see forecasted sales to 2023 at overall world market, submarket, product, and national level. You also assess emerging technologies. Try our new report.
Analysis of what shapes the IBD drugs industry and determines its potential
Discover what the future holds for agents treating inflammatory bowel disorders: Crohn's disease and ulcerative colitis. Read on, then, to explore that drug industry and see what its future market could be worth.
Forecasts to 2023 and other data show you commercial potentials
Besides revenue forecasting, our new work shows recent results, growth rates, and market shares. You discover original quantitative and qualitative analysis, seeing business outlooks and developments (R&D). You also get 74 tables, 34 charts, and three interviews.
You know how hard it can be to find data. All that searching. Now, though, you can stay ahead in knowledge for IBD medicine, benefiting your research, analyses, and decisions.
Avoid falling behind. Also save time. Finding information you need just got easier. There, in our study, you hear what's happening and see where the money lies.
The following sections, then, show what you get in our new investigation.
Prospects for the world market and submarkets for IBD medicationsOur report shows revenue to 2023 for the overall world IBD drug market. It also shows you individual forecasts for five submarkets:
• Biologic therapies (biological drugs)
How will those colonic medicines perform? Which classes of lower-gut treatment will generate most money? There you assess prospects for revenue growth.
Our study gives you a feel for what stimulates and restrains that industry and market. That analysis helps you identify potential for those intestinal medicines. See how you can benefit.
You also find revenue predictions for leading products.
Forecasts for IBD drugs - what outlooks for sales?
How will top drugs perform to 2023 at world level? Our report forecasts individual revenues of 14 products, including these:• Humira• Remicade• Asacol• Pentasa• Lialda• Tysabri• Xifaxan• Cimzia• Entocort.
There you discover how high sales can go, to 2023, finding products and years with highest predicted growth and revenues. Also you examine competition. You see what's happening, then, understanding trends, competition, challenges, and opportunities.
Our investigation also divides its overall IBD world forecast into geographical regions.
National markets for treating those gastrointestinal disorders
Developments worldwide expand the inflammatory bowel treatment market. Hear about the best revenue prospects.
In developed and developing countries, many opportunities for producers and sellers of those drugs will occur from 2013 to 2023. See where and how.
Our analyses show you individual revenue forecasts to 2023 for 11 national markets:• US• Japan• Germany, France, UK, Italy, and Spain (EU5)• China, India, Brazil, and Russia (BRIC).
There you discover progress and outlooks. Product launches from 2013 to 2023 will change the commercial landscape.
Research and development - assess innovation, trends, and possibilitiesWhat about R&D - pipelines for new drugs? You assess trends there, including for these agents:
• Interleukin (IL) inhibitors
• Cell-adhesion molecule (CAM) inhibitors
• TNF alpha inhibitors
• Stem cell therapies
• Chemokine receptors
• Antioxidants and barrier function therapies.
That R&D explores many molecular pathways and targets. It holds promise. You hear about innovations there - developments and their significance. Discover progress.
For large companies and specialty pharma firms there exist many opportunities. Our new study explains, discussing issues to help your work.
Issues affecting manufacturing and selling of IBD treatmentsOur report also shows you issues and events affecting that industry and market from 2013, including these:
• Nature of ulcerative colitis and Crohn's disease
• Aetiology and epidemiology of IBD
• Monoclonal antibodies (mAbs) as medications
• Delivery systems for agents
• Vaccines and alternative therapy
• Genotyping and improvements to treatments.
There you explore political, economic, social, and technological questions, assessing outlooks for the business. You also analyse that industry's strengths, weaknesses, opportunities, and threats. Discover now what the future holds.
Companies leading that industry and 2017 market value
From 2013, new treatments hold great potential for investment, technological advances and high revenues. Our study predicts the world market for IBD drugs will reach $9.6bn in 2017, and expand further to 2023.
Our work shows you what technologies, products, and organisations hold greatest potential. In particular, it investigates these companies:
• Janssen Biotech
• Warner Chilcott
• Shire Pharmaceuticals.
From 2013 there exist prospects for new drugs and overall sales growth. Our report shows you the possibilities, helping you stay ahead.
Eight ways Inflammatory Bowel Diseases: World Drug Market 2013-2023 helps you
To sum up, then, our research and analysis give you the following knowledge:• Revenue to 2023 of the world market for IBD medicines - discover that industry's overall sales potential• Revenues to 2023 for 5 world-level submarkets - investigate the potential of its components, finding the most promising places for investments and sales• Revenues to 2023 for 14 products - find sales outlooks for top brands, seeing how they can compete and succeed• Forecasts to 2023 for 11 national markets in the Americas, Europe, and Asia - discover the best countries for revenues and potential growth• Assessments of top companies - hear about participants' activities, capabilities, results, and outlooks• Review of R&D - explore progress in research and development, finding technological and medical possibilities• Interviews with authorities on the field - discover debates and opinions to help you stay ahead• Competition and opportunities - investigate what shapes that market's future, including ways to develop business and succeed.
Information found nowhere else
That work gives independent analysis. You receive business intelligence found only in our new report, discovering where prospects are most rewarding.
With our study you are less likely to fall behind in knowledge or miss opportunity for treating those gastrointestinal diseases. See there how you could benefit your research, analyses, and decisions. Also find how you can save time and get recognition for commercial insight.
Treatment of IBD - assess its potential now, seeing what you can gainOur new study shows you data, trends, opportunities, and sales predictions for drugs treating inflammatory bowel disorders. Avoid missing out - please order our report now.
Visiongain is a trading partner with the US Federal GovernmentCCR Ref number: KD4R6
Table of Contents1. Executive Summary 1.1 Inflammatory Bowel Disease Market Overview
1.2 Aims, Scope and Format of the Report
1.3 Chapter Outlines
1.4 Research and Analysis Methods
2. Introduction to the Inflammatory Bowel Disease Market
2.1 What is Inflammatory Bowel Disease (IBD)?
2.2 Are There Different Types of IBD?
2.3 Signs, Symptoms and Associated Conditions
2.4 What Causes Inflammatory Bowel Disease?
2.5 How Common is Inflammatory Bowel Disease?
3. Drug Treatments for Inflammatory Bowel Diseases
3.1 Can IBD be Cured?
3.2 What Are the Medications Used to Treat IBD?
3.2.1 Aminosalicylates - The Most Common Therapy
3.2.2 Corticosteroids - Limited in the Long-Run?
3.2.3 Immunomodulators - Slow to Act?
3.2.4 Monoclonal Antibodies - The Future?
3.2.5 Antibiotics - Do they Really Help?
3.3 Treatment Protocol
4. The World Inflammatory Bowel Disease Market, 2013-2023
4.1 The Inflammatory Bowel Disease Market in 2012: Domination of Biologics and Aminosalicylates
4.2 Forecast 2013-2023: Any Major Changes Expected?
4.3 Aminosalicylates Forecast 2013-2023: The Work-Horse of IBD Therapy
4.4 Antibiotics Forecast 2013-2023: Will They Still Be Relevant in a Decade?
4.5 Biologic Therapies Forecast 2013-2023: Main Driver of Growth
4.6 Corticosteroids Forecast 2013-2023: Continued Insignificance?
4.7 Immunomodulators Forecast 2013-2023
5. Leading National Markets, 2013-2023
5.1 IBD Drugs - Leading National Markets, 2012
5.2 The US IBD Drug Market, Revenues 2013-2023 - Leader of the Pack
5.2.1 Case Study: What is the Relative Contribution of Ulcerative Colitis and Crohn's Disease to Total IBD Spending in the US?
5.3 The Japanese IBD Drug Market, Revenues 2013-2023 - Tomorrow's Leader?
5.4 The EU-5 IBD Drug Markets, Revenues 2013-2023 - Europe's Growth Potential
5.5 IBD Drug Markets in BRIC Countries, Revenues 2013-2023 - Vast Potential for Sales
5.5.1 Brazil: Revenues 2013-2023
5.5.2 Russia: Revenues 2013-2023
5.5.3 India: Revenues 2013-2023
5.5.4 China: Revenues 2013-2023
6. Market Prospects for Leading IBD Drugs, 2013-2023
6.1 Humira (AbbVie) - The Leading Therapy
6.1.1Humira: Forecast and Analysis, 2013-2023
6.2 Remicade (Janssen Biotech) - A Worthy Challenger?
6.2.1Remicade: Forecast and Analysis, 2013-2023
6.3 Asacol (Warner Chilcott) - The Best Mesalazine Formulation?
6.3.1Asacol: Forecast and Analysis, 2013-2023
6.4 Pentasa (Shire USA) - When Will a Generic Substitute Arrive?
6.4.1 Pentasa: Forecast and Analysis, 2013-2023
6.5 Lialda (Shire USA) - What Potential for that Medication?
6.5.1 Lialda: Forecast and Analysis, 2013-2023
6.6 Tysabri (Elan Pharmaceuticals) - Will Side Effects Prove Too Much?
6.6.1 Tysabri: Forecast and Analysis, 2013-20236.7 Xifaxan (Salix Pharmaceuticals)
6.7.1 Xifaxan: Forecast and Analysis, 2013-20236.8 Cimzia (UCB Inc.) - Approved in Only a Handful of Countries
6.8.1 Cimzia: Forecast and Analysis, 2013-2023
6.9 Entocort (AstraZeneca) - Prominent Steroid Treatment
6.9.1 Entocort: Forecast and Analysis, 2013-2023
6.10 Neoral (Novartis) - A Widely Used Immunosuppressant
6.10.1 Neoral: Forecast and Analysis, 2013-2023
6.11 Medrol (Pfizer Inc.) - Another Leading Steroid
6.11.1 Medrol: Forecast and Analysis, 2013-2023
6.12 Canasa/Salofalk (Aptalis Pharmaceuticals) - A Slow Decline
6.12.1 Canasa/Salofalk: Forecast and Analysis, 2013-2023
6.13 Apriso (Salix Pharmaceuticals) - A Serious Challenger to Asacol?
6.13.1 Apriso: Forecast and Analysis, 2013-2023
6.14 Azulfidine (Pfizer Inc.) - What Scope for Revenue Growth?
6.14.1 Azulfidine: Forecast and Analysis, 2013-2023
7. The R&D Pipeline for Inflammatory Bowel Disease, 2013
7.1 Interleukin (IL) Inhibitors - One of the Main Areas of Innovation
7.1.1 Profile: Vidofludimus (4SC)
7.2 Cell-Adhesion Molecule (CAM) Inhibitors - A Promising Avenue
7.2.1 Profile: Etrolizumab (Roche)
7.3 TNF-? Inhibitors - A Tried and Tested Target
7.3.1 Profile: Ozoralizumab (Ablynx)
7.4 Stem Cell Therapies - Basis for a Cure?
7.4.1 Profile: Remestemcel-L (Osiris Therapeutics)
7.5 Janus Kinase (JAK) Inhibitors - More Targets to Hit
7.5.1 Profile: Tasocitinib (Pfizer)
7.6 Immunomodulators - Will They Live Up To the Hype?
7.6.1 Profile: ZP1848 (Zealand Pharma)
7.7 Chemokine Receptors - Potential Exists
7.7.1 Profile: Vercirnon (ChemoCentryx/GSK)
7.8 Antioxidants and Barrier Function
7.8.1 Profile: Tetomilast (Otsuka) - The Future of IBD Treatment?
8. Drivers and Restraints in the Inflammatory Bowel Disease Drug Industry and Market, 2013-2023
8.1 SWOT and STEP Analysis of the IBD Market
8.2 What Factors Will Drive the IBD Market?
8.2.1 Increasing Disease Incidence
8.2.2 Better Diagnosis
8.2.3 Nature of the Disease
8.2.4 Delivery Systems
8.2.5 Biological Drugs
8.2.6 Socioeconomic Costs of IBD
8.3 What Factors Will Restrain the Market?
8.3.1 Lack of Understanding of Disease Aetiology
8.3.3 Limits of Biologics
8.3.4 A Cure or Vaccine
8.3.5 The Possible Development of Alternative Treatments
8.3.6 Surgery - When Other Options Fail
9. Leading Companies in the IBD Market, 2013
9.1 The Largest Companies by Revenue
9.2 AbbVie - The Leader in a Highly Profitable Area
9.3 Janssen Biotech - Tomorrow's Powerhouse?
9.4 Warner Chilcott - A Strong Competitor
9.5 Shire Pharmaceuticals - Still a Major Player in the Future?
10. Research Interviews
10.1 Dr Qamar ul Arfin, Gastroenterologist, Aga Khan University Hospital, Karachi, Pakistan
10.1.1 On Antibiotics in Treating IBD
10.1.2 On the Emergence of Biologic Therapies
10.1.3 On IBD in the Pakistani Context
10.1.4 On Any Preventative Measures that Can Be Taken
10.2 Professor John Hermon-Taylor, King's College London
10.2.1 The Significance of MAP in Crohn's
10.2.2 Rising Incidence of IBD
10.2.3 Defining IBD
10.2.4 Timeframe of MAP Vaccine
10.2.5 Antibiotic Activity of Other Crohn's Treatments
10.2.6 Alternative Treatments
10.2.7 Ethics of Crohn's Drug Development
10.2.8 The Impact of a Vaccine on the Market
10.2.9 On Claims that MAP is Not Implicated in CD
10.3 Professor Thomas Barody, Director, Centre for Digestive Diseases, Sydney
10.3.1 Mycobacterium Avium Paratuberculosis (MAP) Infection and IBD Aetiology
10.3.2 IBD and HIV/AIDS
10.3.3 Monoclonal Antibodies and Immunosuppressant Treatments
10.3.4 Potential Cure?
10.3.5 Remicade and MAP10.3.6 Genotyping
10.3.7 Crohn's vs. Colitis
10.3.8 Future Therapies
10.3.9 The Potential and Future of Myoconda
11.1 IBD Market to Expand from 2013 to 2023
11.2 Aminosalicylates and Other Non-Biologic Treatments
11.3 Biologic Treatments
11.4 Improvements Needed in IBD Treatments
11.5 Future IBD Treatments: R&D Efforts Look Promising
11.6 The IBD Sector: Looking to the Future with Confidence
List of TablesTable 2.1 World Incidence Rates for IBD, 2013
Table 2.2 Geographical Variations in the Incidence of IBD, 2013
Table 3.1 Other Drug Types Used to Treat IBD, 2013
Table 4.1 Global IBD Drug Sales ($m), Annual Growth Rates (%) and Market Shares (%) by Segment, 2011 and 2012
Table 4.2 Global IBD Drug Market Forecast ($m), 2012-2023
Table 4.3 Global IBD Drug Forecast by Drug Category ($m), 2012-2023
Table 4.4 Global IBD Drug Market Drivers and Restraints, 2012-2023
Table 4.5 Global Aminosalicylates Forecast ($m), 2012-2023
Table 4.6 Global Aminosalicylates Drivers and Restraints, 2012-2023
Table 4.7 Global Antibiotics Forecast ($m), 2012-2023
Table 4.8 Global Antibiotics Drivers and Restraints, 2012-2023
Table 4.9 Global Biologic Therapies Forecast ($m), 2012-2023
Table 4.10 Global Biologic Therapies Drivers and Restraints, 2012-2023
Table 4.11 Global Corticosteroid Forecast ($m), 2012-2023
Table 4.12 Global Corticosteroids Drivers and Restraints, 2012-2023
Table 4.13 Global Immunomodulators Forecast ($m), 2012-2023
Table 4.14 Global Immunomodulators Drivers and Restraints, 2012-2023
Table 5.1 Global IBD Drug Revenues by Geographical Segments ($m), 2012
Table 5.2 Global IBD Drug Market Forecasts by Country ($m), 2012-2023
Table 5.3 US IBD Drug Market Forecast ($m), 2012-2023
Table 5.4 Japanese IBD Drug Market Forecast ($m), 2012-2023
Table 5.5 EU5 IBD Drug Market Forecasts ($m), 2012-2023
Table 5.6 BRIC IBD Drug Market Forecasts ($m), 2012-2023
Table 5.7 Brazilian IBD Drug Market Forecast ($m), 2012-2023
Table 5.8 Russian IBD Drug Market Forecast ($m), 2012-2023
Table 5.9 Indian IBD Drug Market Forecast ($m), 2012-2023
Table 5.10 Chinese IBD Drug Market Forecast ($m), 2012-2023
Table 6.1 Leading IBD Treatments by Revenue ($m), 2012
Table 6.2 Leading IBD Medicines: Revenue Forecasts ($m), 2012-2023
Table 6.3 World Humira Revenue Forecast ($m), 2012-2023
Table 6.4 Drivers and Restraints for Humira, 2012-2023
Table 6.5 World Remicade Revenue Forecast ($m), 2012-2023
Table 6.6 Drivers and Restraints for Remicade, 2012-2023
Table 6.7 World Asacol Revenue Forecast ($m), 2012-2023
Table 6.8 Drivers and Restraints for Asacol, 2012-2023
Table 6.9 World Pentasa Revenue Forecast ($m), 2012-2023
Table 6.10 Drivers and Restraints for Pentasa, 2012-2023
Table 6.11 World Lialda Revenue Forecast ($m), 2012-2023
Table 6.12 Drivers and Restraints for Lialda, 2012-2023
Table 6.13 World Tysabri Revenue Forecast ($m), 2012-2023
Table 6.14 Drivers and Restraints for Tysabri, 2012-2023
Table 6.15 World Xifaxan Revenue Forecast ($m), 2012-2023
Table 6.16 Drivers and Restraints for Xifaxan, 2012-2023
Table 6.17 World Cimzia Revenue Forecast ($m), 2012-2023
Table 6.18 Drivers and Restraints for Cimzia, 2012-2023
Table 6.19 World Entocort Revenue Forecast ($m), 2012-2023
Table 6.20 Drivers and Restraints for Entocort, 2012-2023
Table 6.21 World Neoral Revenue Forecast ($m), 2012-2023
Table 6.22 Drivers and Restraints for Neoral, 2012-2023
Table 6.23 World Medrol Revenue Forecast ($m), 2012-2023
Table 6.24 Drivers and Restraints for Medrol, 2012-2023
Table 6.25 World Canasa Revenue Forecast ($m), 2012-2023
Table 6.26 Drivers and Restraints for Canasa, 2012-2023
Table 6.27 World Apriso Revenue Forecast ($m), 2012-2023
Table 6.28 Drivers and Restraints for Apriso, 2012-2023
Table 6.29 World Azulfidine Revenue Forecast ($m), 2012-2023
Table 6.30 Drivers and Restraints for Azulfidine, 2012-2023
Table 7.1 Selected IL Inhibitors in Clinical Development, 2013
Table 7.2 Selected CAM Inhibitors in Clinical Development, 2013
Table 7.3 Selected TNF-Alfa Inhibitors in Clinical Development, 2013
Table 7.4 Selected Stem Cell Therapies in Clinical Development, 2013
Table 7.5 Selected Immunomodulators in Clinical Development, 2013
Table 7.6 Selected Chemokine Receptors in Clinical Development, 2013
Table 7.7 Selected Antioxidants and Barrier Function Therapies in Clinical Development, 2013
Table 8.1 SWOT Analysis of the World IBD Drug Market, 2012-2023
Table 8.2 STEP Analysis of the World IBD Drug Market, 2012-2023
Table 9.1 Top 4 Companies for IBD Drugs: Revenues ($m) and Market Shares (%), 2012
Table 9.2 AbbVie Revenues ($m) and Market Share (%), 2012
Table 9.3 Janssen Biotech Revenues ($m) and Market Share (%), 2012
Table 9.4 Warner Chilcott Revenues ($m) and Market Share (%), 2012
Table 9.5 Shire's Revenues ($m) and Market Share (%), 2012
Table 11.1 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Shares (%) by Product Category, 2013, 2017, 2023
Table 11.2 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Shares (%) by Geographical Regions, 2013, 2017, 2023
Table 11.3 Summary of IBD Market Drivers and Restraints, 2013-2023
List of FiguresFigure 3.1 Treatment Protocol for IBD, 2013
Figure 4.1 World IBD Drugs Market Shares by Product Type (%), 2012
Figure 4.2 Global IBD Drug Market Forecast ($m), 2012-2023
Figure 4.3 World IBD Drugs Market Shares by Product Type (%), 2023
Figure 4.4 Global Aminosalicylates Forecast ($m), 2012-2023
Figure 4.5 Global Antibiotics Forecast ($m), 2012-2023
Figure 4.6 Global Biologic Therapies Forecast ($m), 2012-2023
Figure 4.7 Global Corticosteroid Forecast ($m), 2012-2023
Figure 4.8 Global Immunomodulators Forecast ($m), 2012-2023
Figure 5.1 Global IBD Drug Market by Geographical Segments (%), 2012
Figure 5.2 Global IBD Drug Market by Geographical Segments (%), 2023
Figure 5.3 US IBD Drug Market Forecast ($m), 2012-2023
Figure 5.4 Japanese IBD Drug Market Forecast ($m), 2012-2023
Figure 5.5 EU5 IBD Drug Market Forecasts ($m), 2012-2023
Figure 5.6 BRIC IBD Drug Market Forecasts ($m), 2012-2023
Figure 5.7 Brazilian IBD Drug Market Forecast ($m), 2012-2023
Figure 5.8 Russian IBD Drug Market Forecast ($m), 2012-2023
Figure 5.9 Indian IBD Drug Market Forecast ($m), 2012-2023
Figure 5.10 Chinese IBD Drug Market Forecast ($m), 2012-2023
Figure 6.1 World Humira Revenue Forecast ($m), 2012-2023
Figure 6.2 World Remicade Revenue Forecast ($m), 2012-2023
Figure 6.3 World Asacol Revenue Forecast ($m), 2012-2023
Figure 6.4 World Pentasa Revenue Forecast ($m), 2012-2023
Figure 6.5 World Lialda Revenue Forecast ($m), 2012-2023
Figure 6.6 World Tysabri Revenue Forecast ($m), 2012-2023
Figure 6.7 World Xifaxan Revenue Forecast ($m), 2012-2023
Figure 6.8 World Cimzia Revenue Forecast ($m), 2012-2023
Figure 6.9 World Entocort Revenue Forecast ($m), 2012-2023
Figure 6.10 World Neoral Revenue Forecast ($m), 2012-2023
Figure 6.11 World Medrol Revenue Forecast ($m), 2012-2023
Figure 6.12 World Canasa Revenue Forecast ($m), 2012-2023
Figure 6.13 World Apriso Revenue Forecast ($m), 2012-2023
Figure 6.14 World Azulfidine Revenue Forecast ($m), 2012-2023
Figure 9.1 Top 4 Companies for IBD Drugs: Market Shares (%), 2012
Aga Khan University Hospital
Cambridge Antibody Technology
Celgene Cellular Therapies
Centocor Ortho Biotech
Centre for Digestive Diseases, Sydney
Centres for Disease Control and Prevention
Crohn's and Colitis Foundation of America
Crohn's and Colitis Foundation of Canada
European Federation of Crohn's and Ulcerative Colitis Associations
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Johnson & Johnson
King's College London
Kyorin Pharmaceutical Co.
Merck & Co.
Otsuka Pharmaceutical Group
Probiotic Therapy Research Centre, Sydney, Australia
Procter & Gamble Pharmaceuticals
Shire Pharmaceuticals Group
Teva Pharmaceutical Industries
World Gastroenterology Organisation (WGO)
To order this report:Drug_and_Medication Industry: Inflammatory Bowel Diseases: World Drug Market 2013-2023
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
Between the mockups and specs produced by analysts, and resulting applications built by developers, there exists a gulf where projects fail, costs spiral, and applications disappoint. Methodologies like Agile attempt to address this with intensified communication, with partial success but many limitations. In his session at 18th Cloud Expo, Charles Kendrick, CTO & Chief Architect at Isomorphic Software, will present a revolutionary model enabled by new technologies. Learn how business and devel...
May. 2, 2016 04:30 AM EDT Reads: 1,750
So, you bought into the current machine learning craze and went on to collect millions/billions of records from this promising new data source. Now, what do you do with them? Too often, the abundance of data quickly turns into an abundance of problems. How do you extract that "magic essence" from your data without falling into the common pitfalls? In her session at @ThingsExpo, Natalia Ponomareva, Software Engineer at Google, will provide tips on how to be successful in large scale machine lear...
May. 2, 2016 01:45 AM EDT Reads: 1,269
The IoT has the potential to create a renaissance of manufacturing in the US and elsewhere. In his session at 18th Cloud Expo, Florent Solt, CTO and chief architect of Netvibes, will discuss how the expected exponential increase in the amount of data that will be processed, transported, stored, and accessed means there will be a huge demand for smart technologies to deliver it. Florent Solt is the CTO and chief architect of Netvibes. Prior to joining Netvibes in 2007, he co-founded Rift Technol...
May. 1, 2016 11:00 PM EDT Reads: 1,589
If there is anything we have learned by now, is that every business paves their own unique path for releasing software- every pipeline, implementation and practices are a bit different, and DevOps comes in all shapes and sizes. Software delivery practices are often comprised of set of several complementing (or even competing) methodologies – such as leveraging Agile, DevOps and even a mix of ITIL, to create the combination that’s most suitable for your organization and that maximize your busines...
May. 1, 2016 08:00 PM EDT Reads: 1,845
The increasing popularity of the Internet of Things necessitates that our physical and cognitive relationship with wearable technology will change rapidly in the near future. This advent means logging has become a thing of the past. Before, it was on us to track our own data, but now that data is automatically available. What does this mean for mHealth and the "connected" body? In her session at @ThingsExpo, Lisa Calkins, CEO and co-founder of Amadeus Consulting, will discuss the impact of wea...
May. 1, 2016 07:00 PM EDT Reads: 750
See storage differently! Storage performance problems have only gotten worse and harder to solve as applications have become largely virtualized and moved to a cloud-based infrastructure. Storage performance in a virtualized environment is not just about IOPS, it is about how well that potential performance is guaranteed to individual VMs for these apps as the number of VMs keep going up real time. In his session at 18th Cloud Expo, Dhiraj Sehgal, in product and marketing at Tintri, will discu...
May. 1, 2016 06:00 PM EDT Reads: 813
SYS-CON Events announced today that Peak 10, Inc., a national IT infrastructure and cloud services provider, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Peak 10 provides reliable, tailored data center and network services, cloud and managed services. Its solutions are designed to scale and adapt to customers’ changing business needs, enabling them to lower costs, improve performance and focus inter...
May. 1, 2016 06:00 PM EDT Reads: 1,160
We’ve worked with dozens of early adopters across numerous industries and will debunk common misperceptions, which starts with understanding that many of the connected products we’ll use over the next 5 years are already products, they’re just not yet connected. With an IoT product, time-in-market provides much more essential feedback than ever before. Innovation comes from what you do with the data that the connected product provides in order to enhance the customer experience and optimize busi...
May. 1, 2016 05:00 PM EDT Reads: 1,031
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...
May. 1, 2016 04:30 PM EDT Reads: 1,480
In his session at @ThingsExpo, Chris Klein, CEO and Co-founder of Rachio, will discuss next generation communities that are using IoT to create more sustainable, intelligent communities. One example is Sterling Ranch, a 10,000 home development that – with the help of Siemens – will integrate IoT technology into the community to provide residents with energy and water savings as well as intelligent security. Everything from stop lights to sprinkler systems to building infrastructures will run ef...
May. 1, 2016 04:00 PM EDT Reads: 947
SYS-CON Events announced today that Enzu, a leading provider of cloud hosting solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Enzu’s mission is to be the leading provider of enterprise cloud solutions worldwide. Enzu enables online businesses to use its IT infrastructure to their competitive advantage. By offering a suite of proven hosting and management services, Enzu wants companies to foc...
May. 1, 2016 03:15 PM EDT Reads: 1,039
Digital payments using wearable devices such as smart watches, fitness trackers, and payment wristbands are an increasing area of focus for industry participants, and consumer acceptance from early trials and deployments has encouraged some of the biggest names in technology and banking to continue their push to drive growth in this nascent market. Wearable payment systems may utilize near field communication (NFC), radio frequency identification (RFID), or quick response (QR) codes and barcodes...
May. 1, 2016 01:30 PM EDT Reads: 820
SYS-CON Events announced today that Stratoscale, the software company developing the next generation data center operating system, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Stratoscale is revolutionizing the data center with a zero-to-cloud-in-minutes solution. With Stratoscale’s hardware-agnostic, Software Defined Data Center (SDDC) solution to store everything, run anything and scale everywhere...
May. 1, 2016 01:30 PM EDT Reads: 1,581
Angular 2 is a complete re-write of the popular framework AngularJS. Programming in Angular 2 is greatly simplified – now it's a component-based well-performing framework. This immersive one-day workshop at 18th Cloud Expo, led by Yakov Fain, a Java Champion and a co-founder of the IT consultancy Farata Systems and the product company SuranceBay, will provide you with everything you wanted to know about Angular 2.
May. 1, 2016 01:00 PM EDT Reads: 1,753